Simulating costs of intravenous biosimilar trastuzumab vs. Subcutaneous reference trastuzumab in adjuvant her2-positive breast cancer: A belgian case study

Steven Simoens*, Arnold G. Vulto, Pieter Dylst

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
10 Downloads (Pure)

Abstract

This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and colleagues, and considered costs of drugs, healthcare professional time and consumables. We calculated intravenous drug costs for different body weights, and computed drug costs and healthcare costs to treat 100 patients with either trastuzumab formulation, assuming a binomial body weight distribution in this sample. Scenarios were run to account for drug discounts and intravenous vial sharing. Drug costs amounted to €1,431,282 with intravenous biosimilar trastuzumab and €1,522,809 with subcutaneous reference trastuzumab for a sample of 100 patients in the base case analysis. When healthcare professional time and consumables were also considered, healthcare costs with intravenous biosimilar trastuzumab were similar to those with subcutaneous reference trastuzumab. Differences in healthcare costs between intravenous biosimilar trastuzumab and subcutaneous reference trastuzumab depended on the level of discounts on these formulations and on intravenous vial sharing. Our case study demonstrates that comparing costs of intravenous vs. subcutaneous formulations is complex and multifactorial, and entails more than a simple cost comparison of products.

Original languageEnglish
Article number450
JournalPharmaceuticals
Volume14
Issue number5
DOIs
Publication statusPublished - 11 May 2021

Bibliographical note

Funding Information:
Acknowledgments: Medical writing support was provided by Peter Todd of Tajut Ltd. (Kaiapoi, New Zealand) and was funded by Mundipharma Comm. VA (Mechelen, Belgium).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Fingerprint

Dive into the research topics of 'Simulating costs of intravenous biosimilar trastuzumab vs. Subcutaneous reference trastuzumab in adjuvant her2-positive breast cancer: A belgian case study'. Together they form a unique fingerprint.

Cite this